Who
Leesa Gentry
Chief Clinical Officer
Company insider
Files Form 4 as: Chief Clinical Officer, RenovoRx.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 6 Mar 2024
- Last trade
- 3 Apr 2026
- Last filed
- 7 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —128,550 at $0.00 | filing |
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —128,550 at $0.00 | filing |
| 1 Jul 2025filed 3 Jul 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,619 at $0.00 | filing |
| 14 Apr 2025filed 16 Apr 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,477 at $0.00 | filing |
| 6 Mar 2024filed 8 Mar 2024 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.